ACE2 and neoplasm: In the subcutaneous cell-derived xenograft models, the high tumor uptake (6.74 ± 0.31% ID/mL at 1.5 h post-injection; 3.14 ± 0.31% ID/mL at 4.5 h post-injection) was observed in the pancreas of ACE2-positive HEK293T/hACE2 mice compared with ACE2-negative HEK293T mice (1.83 ± 0.26% ID/mL at 1.5 h post-injection; 1.16 ± 0.15% ID/mL at 4.5 h post-injection).